UW TAN Study of Metastatic Urothelial Carcinoma

Patients with metastatic urothelial carcinoma treated at our institution, who elected to undergo rapid autopsy at the time of death, are included in this study. These patients agreed to submit their tissue (normal samples for germline analysis [kidney or liver] as well as primary and metastatic tumor sites [urothelial carcinoma]) and the time of autopsy. Each patient signed consent to allow study of these tissues including histologic, sequencing (DNA/RNA), and implantation in to animals as able for future study.]]> Inclusion criteria: Patients with metastatic urothelial carcinoma treated at our institution near the time of death. Other therapies given prior to transferring care to our institution were allowed. All races and genders were included. Exclusion criteria: No exclusions based on disease, race, gender, or any demographics. As urothelial carcinoma is a disease of older age people, minors and pregnant women were not included.]]> The University of Washington rapid autopsy program was initially developed in prostate cancer. Using these tools and experiences, the bladder rapid autopsy program was developed, first started in 2015. These data are contributed by the first 7 patients from the program.]]>